Edric EngertSenior Vice President Biosimilars
Edric Engert is currently Senior Vice President and Head of Biosimilars for Teva Pharmaceuticals. He is responsible for all aspects of the business, from portfolio strategy and selection through BD and operations to go-to-market strategies and execution. He has recently built both the Biosimilars and Novel Biologics strategies for Teva. His prior role at Teva was global head of Portfolio Management & In-licensing for their Generics business where he also co-led the creation of their Generics Strategy. Other prior positions include Managing Director of Abraxeolus Consulting where he assisted clients in pharma, biotech, API, devices, and retailers/wholesalers in strategy, portfolio, operational turnarounds, and M&A; Global Head of Portfolio Management & In-licensing at Sandoz; VP of Strategic Planning, Portfolio, and API Sourcing at Geneva Pharmaceuticals; and consultant at McKinsey & Company’s health care practice. Edric holds an MBA from Wharton and a BS in Mathematics from MIT.